Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02843204

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Sponsor: Fuda Cancer Hospital, Guangzhou

Interventions NK immunotherapy Pembrolizumab

Updated 8 times since 2017 Last updated: May 26, 2020 Started: Jul 1, 2016 Primary completion: Jul 1, 2017 Completion: Jul 1, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02843204, this PHASE1/PHASE2 trial focuses on Malignant Solid Tumour and remains completed. Sponsored by Fuda Cancer Hospital, Guangzhou, it has been updated 8 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Oct 2019 — Jun 2020 [monthly]

Completed PHASE1_PHASE2

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Aug 2019 — Oct 2019 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Aug 2019 [monthly]

Recruiting PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fuda Cancer Hospital, Guangzhou
Shenzhen Hank Bioengineering Institute

Data source: Fuda Cancer Hospital, Guangzhou

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China